Saudi Arabia Approves Fundoia for Obesity
The Saudi Food and Drug Authority (SFDA) has announced the approval of Fundoayo for the treatment of obesity, which helps to achieve long-term weight loss in adults with obesity or overweight conditions accompanied by related health issues. The medication works by activating GLP-1 receptors to regulate appetite and blood sugar levels, thereby reducing food intake and supporting weight loss. Studies have shown that the highest dose of Fundoayo (36 mg) resulted in an average reduction in body weight of 11.2% over 72 weeks in a group of 3,127 non-diabetic individuals, and 9.6% in a group of 1,613 individuals with obesity and type 2 diabetes. This approval is part of efforts to improve treatment options and expand access to obesity management therapies in Saudi Arabia.
Notice: This Is an AI-Generated Summary
Comments (0)